Human Gene AKT1 (uc001ypm.3)
  Description: Homo sapiens v-akt murine thymoma viral oncogene homolog 1 (AKT1), transcript variant 2, mRNA.
RefSeq Summary (NM_001014432): This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020].
Transcript (Including UTRs)
   Position: hg19 chr14:105,235,687-105,262,080 Size: 26,394 Total Exon Count: 15 Strand: -
Coding Region
   Position: hg19 chr14:105,236,678-105,258,980 Size: 22,303 Coding Exon Count: 13 

Page IndexSequence and LinksUniProtKB CommentsPrimersGenetic AssociationsMalaCards
CTDGene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein Structure
Other SpeciesGO AnnotationsmRNA DescriptionsPathwaysOther NamesGeneReviews
Model InformationMethods
Data last updated at UCSC: 2013-06-14

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr14:105,235,687-105,262,080)mRNA (may differ from genome)Protein (480 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
GeneNetworkH-INVHGNCLynxMalacardsMGI
neXtProtOMIMPubMedReactomeTreefamUniProtKB
WikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: AKT1_HUMAN
DESCRIPTION: RecName: Full=RAC-alpha serine/threonine-protein kinase; EC=2.7.11.1; AltName: Full=Protein kinase B; Short=PKB; AltName: Full=Protein kinase B alpha; Short=PKB alpha; AltName: Full=Proto-oncogene c-Akt; AltName: Full=RAC-PK-alpha;
FUNCTION: AKT1 is one of 3 closely related serine/threonine- protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)- response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr- 117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro- apoptotic activity.
FUNCTION: AKT1-specific substrates have been recently identified, including palladin (PALLD), which phosphorylation modulates cytoskeletal organization and cell motility; prohibitin (PHB), playing an important role in cell metabolism and proliferation; and CDKN1A, for which phosphorylation at 'Thr-145' induces its release from CDK2 and cytoplasmic relocalization. These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation. Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation.
CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
ENZYME REGULATION: Three specific sites, one in the kinase domain (Thr-308) and the two other ones in the C-terminal regulatory region (Ser-473 and Tyr-474), need to be phosphorylated for its full activation. Inhibited by pyrrolopyrimidine inhibitors like aniline triazole and spiroindoline.
BIOPHYSICOCHEMICAL PROPERTIES: Kinetic parameters: KM=52.8 uM for ATP (for purified and in vitro activated AKT1); KM=0.5 uM for peptide substrate (for purified and in vitro activated AKT1); KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and immunoprecipitated from Rat-1 cells); KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 expressed and immunoprecipitated from Rat-1 cells);
SUBUNIT: Interacts (via the C-terminus) with CCDC88A (via its C- terminus). Interacts with GRB10; the interaction leads to GRB10 phosphorylation thus promoting YWHAE-binding (By similarity). Interacts with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) with MTCP1, TCL1A AND TCL1B. Interacts with CDKN1B; the interaction phosphorylates CDKN1B promoting 14-3- 3 binding and cell-cycle progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts with SRPK2 in a phosphorylation- dependent manner. Interacts with RAF1. Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts (via the C- terminus) with THEM4 (via its C-terminus). Interacts with and phosphorylated by PDPK1.
INTERACTION: Self; NbExp=2; IntAct=EBI-296087, EBI-296087; P29067:Arrb2 (xeno); NbExp=2; IntAct=EBI-296087, EBI-1636616; Q8IXJ9:ASXL1; NbExp=2; IntAct=EBI-296087, EBI-1646500; O95999:BCL10; NbExp=4; IntAct=EBI-296087, EBI-958922; Q16543:CDC37; NbExp=2; IntAct=EBI-296087, EBI-295634; P49841:GSK3B; NbExp=2; IntAct=EBI-296087, EBI-373586; Q99683:MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; O60437:PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; Q15047:SETDB1; NbExp=9; IntAct=EBI-296087, EBI-79691; Q96EB6:SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; P08670:VIM; NbExp=29; IntAct=EBI-296087, EBI-353844;
SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane. Note=Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.
TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.
DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3- kinase alpha (PIK3CA) activity results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.
PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating phosphorylation at Thr-308 via disrupting the interaction between AKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with phosphorylation at this site.
PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells. Ser-473 phosphorylation is enhanced by signaling through activated FLT3. Dephosphorylated at Thr-308 and Ser-473 by PP2A phosphatase. The phosphorylated form of PPP2R5B is required for bridging AKT1 with PP2A phosphatase.
PTM: Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading to its degradation by the proteasome (By similarity). Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'- linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'- polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome. Also ubiquitinated by TRIM13 leading to its proteasomal degradation.
PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases EP300 and KAT2B. Acetylation results in reduced phosphorylation and inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. SIRT1-mediated deacetylation relieves the inhibition.
DISEASE: Defects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
DISEASE: Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
DISEASE: Note=Genetic variations in AKT1 may play a role in susceptibility to ovarian cancer.
DISEASE: Defects in AKT1 are a cause of Proteus syndrome (PROTEUSS) [MIM:176920]. A highly variable, severe disorder of asymmetric and disproportionate overgrowth of body parts, connective tissue nevi, epidermal nevi, dysregulated adipose tissue, and vascular malformations. Many features of Proteus syndrome overlap with other overgrowth syndromes.
SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
SIMILARITY: Contains 1 PH domain.
SIMILARITY: Contains 1 protein kinase domain.
CAUTION: In light of strong homologies in the primary amino acid sequence, the 3 AKT kinases were long surmised to play redundant and overlapping roles. More recent studies has brought into question the redundancy within AKT kinase isoforms and instead pointed to isoform specific functions in different cellular events and diseases. AKT1 is more specifically involved in cellular survival pathways, by inhibiting apoptotic processes; whereas AKT2 is more specific for the insulin receptor signaling pathway. Moreover, while AKT1 and AKT2 are often implicated in many aspects of cellular transformation, the 2 isoforms act in a complementary opposing manner. The role of AKT3 is less clear, though it appears to be predominantly expressed in brain.

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  Genetic Association Studies of Complex Diseases and Disorders
  Genetic Association Database (archive): AKT1
CDC HuGE Published Literature: AKT1
Positive Disease Associations: methamphetamine abuse , schizophrenia
Related Studies:
  1. methamphetamine abuse
    Ikeda, M. et al. 2005, Positive association of AKT1 haplotype to Japanese methamphetamine use disorder., The international journal of neuropsychopharmacology. 2006 Feb;9(1):77-81. [PubMed 15982448]
  2. schizophrenia
    Ikeda, M. et al. 2004, Association of AKT1 with schizophrenia confirmed in a Japanese population., Biological psychiatry. 2004 Nov;56(9):698-700. [PubMed 15522255]
    Our study provides support for the theory that AKT1 is a susceptibility gene for Japanese schizophrenia. Fine linkage disequilibrium mapping is required for a conclusive result.
  3. schizophrenia
    Emamian ES 2004, Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia., Nature genetics. 2004 Feb;36(2):131-7. [PubMed 14745448]
           more ... click here to view the complete list

-  MalaCards Disease Associations
  MalaCards Gene Search: AKT1
Diseases sorted by gene-association score: cowden syndrome 6* (1329), proteus syndrome, somatic* (1266), ovarian cancer, somatic* (233), breast cancer* (223), cowden disease* (159), colorectal cancer* (107), thymoma (48), ductal carcinoma in situ (32), schizophrenia* (16), serous cystadenocarcinoma (12), adenocarcinoma (12), renal cell carcinoma (10), hidradenoma (10), insulin-like growth factor i (10), cystadenocarcinoma (9), prostate cancer (9), pancreatic ductal adenocarcinoma (9), pancreatic cancer (8), apical myocardial infarction (8), brain cancer (8), glioblastoma multiforme (8), leopard syndrome (8), hepatopulmonary syndrome (7), colitis (7), salivary gland cancer (7), tuberous sclerosis (7), hepatocellular carcinoma (7), anal squamous cell carcinoma (7), oral squamous cell carcinoma (6), male reproductive organ cancer (6), endometrial cancer (6), estrogen-receptor positive breast cancer (6), macroglobulinemia (6), ovarian serous cystadenocarcinoma (6), primary effusion lymphoma (6), female reproductive organ cancer (5), reproductive organ cancer (5), lung cancer (5), gastrointestinal system cancer (5), kaposi sarcoma (5), mitral valve disease (5), pleural cancer (5), cell type cancer (5), malignant ovarian surface epithelial-stromal neoplasm (5), peripheral nervous system neoplasm (4), autonomic nervous system neoplasm (4), ovary epithelial cancer (4), pancreas adenocarcinoma (4), pharynx cancer (4), testicular germ cell tumor (4), huntington disease (4), kidney cancer (4), ulcerative colitis (4), wiskott-aldrich syndrome (4), astrocytoma (3), mantle cell lymphoma (3), psychotic disorder (3), esophageal cancer (3), gastrointestinal stromal tumor (2), multiple myeloma (2), medulloblastoma (2), glucose metabolism disease (2), acquired metabolic disease (2), diabetes mellitus, noninsulin-dependent (2), nervous system cancer (1), endocrine gland cancer (1), neuroblastoma (1), toxic encephalopathy (1), connective tissue cancer (1), diabetes mellitus, insulin-dependent (1), integumentary system cancer (1), stroke, ischemic (1), macular degeneration, age-related, 1 (1), parkinson disease, late-onset (1), leukemia, acute myeloid (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 51.70 RPKM in Adrenal Gland
Total median expression: 1544.81 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -254.51423-0.602 Picture PostScript Text
3' UTR -393.14991-0.397 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR000961 - AGC-kinase_C
IPR011009 - Kinase-like_dom
IPR011993 - PH_like_dom
IPR017892 - Pkinase_C
IPR001849 - Pleckstrin_homology
IPR000719 - Prot_kinase_cat_dom
IPR017441 - Protein_kinase_ATP_BS
IPR002290 - Ser/Thr_dual-sp_kinase_dom
IPR008271 - Ser/Thr_kinase_AS

Pfam Domains:
PF00069 - Protein kinase domain
PF00169 - PH domain
PF00433 - Protein kinase C terminal domain
PF07714 - Protein tyrosine kinase
PF14531 - Kinase-like

SCOP Domains:
50729 - PH domain-like
56112 - Protein kinase-like (PK-like)

Protein Data Bank (PDB) 3-D Structure
MuPIT help
1H10 - X-ray MuPIT 1UNP - X-ray MuPIT 1UNQ - X-ray MuPIT 1UNR - X-ray MuPIT 2UVM - X-ray MuPIT 2UZR - X-ray 2UZS - X-ray 3CQU - X-ray MuPIT 3CQW - X-ray MuPIT 3MV5 - X-ray MuPIT 3MVH - X-ray MuPIT 3O96 - X-ray MuPIT 3OCB - X-ray MuPIT 3OW4 - X-ray MuPIT 3QKK - X-ray MuPIT 3QKL - X-ray MuPIT 3QKM - X-ray MuPIT 4EJN - X-ray MuPIT 4EKK - X-ray MuPIT 4EKL - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P31749
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologGenome BrowserNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGD    
 Protein Sequence    
 Alignment    

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0000166 nucleotide binding
GO:0004672 protein kinase activity
GO:0004674 protein serine/threonine kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0005080 protein kinase C binding
GO:0005515 protein binding
GO:0005524 ATP binding
GO:0005547 phosphatidylinositol-3,4,5-trisphosphate binding
GO:0016301 kinase activity
GO:0016740 transferase activity
GO:0019899 enzyme binding
GO:0019901 protein kinase binding
GO:0030235 nitric-oxide synthase regulator activity
GO:0032794 GTPase activating protein binding
GO:0042802 identical protein binding
GO:0042803 protein homodimerization activity
GO:0043325 phosphatidylinositol-3,4-bisphosphate binding
GO:0051721 protein phosphatase 2A binding
GO:0071889 14-3-3 protein binding

Biological Process:
GO:0000060 protein import into nucleus, translocation
GO:0001649 osteoblast differentiation
GO:0001893 maternal placenta development
GO:0001934 positive regulation of protein phosphorylation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0005975 carbohydrate metabolic process
GO:0005977 glycogen metabolic process
GO:0005978 glycogen biosynthetic process
GO:0005979 regulation of glycogen biosynthetic process
GO:0006006 glucose metabolic process
GO:0006412 translation
GO:0006417 regulation of translation
GO:0006464 cellular protein modification process
GO:0006468 protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0006809 nitric oxide biosynthetic process
GO:0006915 apoptotic process
GO:0006924 activation-induced cell death of T cells
GO:0006954 inflammatory response
GO:0006974 cellular response to DNA damage stimulus
GO:0006979 response to oxidative stress
GO:0007165 signal transduction
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007186 G-protein coupled receptor signaling pathway
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007275 multicellular organism development
GO:0007281 germ cell development
GO:0007399 nervous system development
GO:0007568 aging
GO:0008283 cell proliferation
GO:0008284 positive regulation of cell proliferation
GO:0008286 insulin receptor signaling pathway
GO:0008637 apoptotic mitochondrial changes
GO:0008643 carbohydrate transport
GO:0009408 response to heat
GO:0009725 response to hormone
GO:0010033 response to organic substance
GO:0010507 negative regulation of autophagy
GO:0010628 positive regulation of gene expression
GO:0010629 negative regulation of gene expression
GO:0010748 negative regulation of plasma membrane long-chain fatty acid transport
GO:0010763 positive regulation of fibroblast migration
GO:0010765 positive regulation of sodium ion transport
GO:0010907 positive regulation of glucose metabolic process
GO:0010918 positive regulation of mitochondrial membrane potential
GO:0010951 negative regulation of endopeptidase activity
GO:0010975 regulation of neuron projection development
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0016242 negative regulation of macroautophagy
GO:0016310 phosphorylation
GO:0016567 protein ubiquitination
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0019221 cytokine-mediated signaling pathway
GO:0021510 spinal cord development
GO:0030030 cell projection organization
GO:0030154 cell differentiation
GO:0030163 protein catabolic process
GO:0030212 hyaluronan metabolic process
GO:0030307 positive regulation of cell growth
GO:0030334 regulation of cell migration
GO:0031018 endocrine pancreas development
GO:0031295 T cell costimulation
GO:0031397 negative regulation of protein ubiquitination
GO:0031641 regulation of myelination
GO:0031659 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0031929 TOR signaling
GO:0031999 negative regulation of fatty acid beta-oxidation
GO:0032079 positive regulation of endodeoxyribonuclease activity
GO:0032091 negative regulation of protein binding
GO:0032094 response to food
GO:0032148 activation of protein kinase B activity
GO:0032270 positive regulation of cellular protein metabolic process
GO:0032287 peripheral nervous system myelin maintenance
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032869 cellular response to insulin stimulus
GO:0032880 regulation of protein localization
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0034405 response to fluid shear stress
GO:0034614 cellular response to reactive oxygen species
GO:0035556 intracellular signal transduction
GO:0035655 interleukin-18-mediated signaling pathway
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0036294 cellular response to decreased oxygen levels
GO:0038061 NIK/NF-kappaB signaling
GO:0042593 glucose homeostasis
GO:0042981 regulation of apoptotic process
GO:0043065 positive regulation of apoptotic process
GO:0043066 negative regulation of apoptotic process
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043276 anoikis
GO:0043488 regulation of mRNA stability
GO:0043491 protein kinase B signaling
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045600 positive regulation of fat cell differentiation
GO:0045725 positive regulation of glycogen biosynthetic process
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045792 negative regulation of cell size
GO:0045861 negative regulation of proteolysis
GO:0045893 positive regulation of transcription, DNA-templated
GO:0045907 positive regulation of vasoconstriction
GO:0045944 positive regulation of transcription from RNA polymerase II promoter
GO:0046326 positive regulation of glucose import
GO:0046329 negative regulation of JNK cascade
GO:0046622 positive regulation of organ growth
GO:0046777 protein autophosphorylation
GO:0046889 positive regulation of lipid biosynthetic process
GO:0048009 insulin-like growth factor receptor signaling pathway
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050999 regulation of nitric-oxide synthase activity
GO:0051000 positive regulation of nitric-oxide synthase activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051146 striated muscle cell differentiation
GO:0051186 cofactor metabolic process
GO:0051898 negative regulation of protein kinase B signaling
GO:0060079 excitatory postsynaptic potential
GO:0060416 response to growth hormone
GO:0060644 mammary gland epithelial cell differentiation
GO:0060709 glycogen cell differentiation involved in embryonic placenta development
GO:0060716 labyrinthine layer blood vessel development
GO:0070141 response to UV-A
GO:0071260 cellular response to mechanical stimulus
GO:0071276 cellular response to cadmium ion
GO:0071356 cellular response to tumor necrosis factor
GO:0071363 cellular response to growth factor stimulus
GO:0071364 cellular response to epidermal growth factor stimulus
GO:0071380 cellular response to prostaglandin E stimulus
GO:0071407 cellular response to organic cyclic compound
GO:0071456 cellular response to hypoxia
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0072655 establishment of protein localization to mitochondrion
GO:0072656 maintenance of protein location in mitochondrion
GO:0090201 negative regulation of release of cytochrome c from mitochondria
GO:0097011 cellular response to granulocyte macrophage colony-stimulating factor stimulus
GO:0097194 execution phase of apoptosis
GO:0100002 negative regulation of protein kinase activity by protein phosphorylation
GO:1900182 positive regulation of protein localization to nucleus
GO:1901215 negative regulation of neuron death
GO:1901653 cellular response to peptide
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1902176 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1903078 positive regulation of protein localization to plasma membrane
GO:1903721 positive regulation of I-kappaB phosphorylation
GO:1990090 cellular response to nerve growth factor stimulus
GO:1990418 response to insulin-like growth factor stimulus
GO:2000010 positive regulation of protein localization to cell surface
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand

Cellular Component:
GO:0005634 nucleus
GO:0005654 nucleoplasm
GO:0005737 cytoplasm
GO:0005739 mitochondrion
GO:0005819 spindle
GO:0005829 cytosol
GO:0005886 plasma membrane
GO:0005911 cell-cell junction
GO:0015630 microtubule cytoskeleton
GO:0016020 membrane
GO:0031982 vesicle
GO:0032991 macromolecular complex
GO:0036064 ciliary basal body
GO:0098794 postsynapse


-  Descriptions from all associated GenBank mRNAs
  BX648205 - Homo sapiens mRNA; cDNA DKFZp686K13249 (from clone DKFZp686K13249).
FW399331 - NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF.
BC000479 - Homo sapiens v-akt murine thymoma viral oncogene homolog 1, mRNA (cDNA clone MGC:8686 IMAGE:2964603), complete cds.
BC084538 - Homo sapiens v-akt murine thymoma viral oncogene homolog 1, mRNA (cDNA clone MGC:99656 IMAGE:6645486), complete cds.
FW399332 - NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF.
FW399333 - NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF.
AK122894 - Homo sapiens cDNA FLJ16549 fis, clone PLACE7003657, highly similar to RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1).
M63167 - Human rac protein kinase alpha mRNA, complete cds.
EU832491 - Synthetic construct Homo sapiens clone HAIB:100067520; DKFZo008E0929 v-akt murine thymoma viral oncogene homolog 1 protein (AKT1) gene, encodes complete protein.
EU832571 - Synthetic construct Homo sapiens clone HAIB:100067600; DKFZo004E0930 v-akt murine thymoma viral oncogene homolog 1 protein (AKT1) gene, encodes complete protein.
AK314256 - Homo sapiens cDNA, FLJ95003, Homo sapiens v-akt murine thymoma viral oncogene homolog 1 (AKT1),mRNA.
KJ890652 - Synthetic construct Homo sapiens clone ccsbBroadEn_00046 AKT1 gene, encodes complete protein.
KJ905141 - Synthetic construct Homo sapiens clone ccsbBroadEn_14538 AKT1 gene, encodes complete protein.
KR710120 - Synthetic construct Homo sapiens clone CCSBHm_00009883 AKT1 (AKT1) mRNA, encodes complete protein.
AB451242 - Homo sapiens AKT1 mRNA for v-akt murine thymoma viral oncogene homolog 1, complete cds, clone: FLJ08041AAAN.
AB451367 - Homo sapiens AKT1 mRNA for v-akt murine thymoma viral oncogene homolog 1, partial cds, clone: FLJ08041AAAF.
KU177898 - Homo sapiens v-akt murine thymoma viral oncogene-like protein 1 isoform 1 (AKT1) mRNA, partial cds.
KU177899 - Homo sapiens v-akt murine thymoma viral oncogene-like protein 1 isoform 2 (AKT1) mRNA, complete cds, alternatively spliced.
AB463340 - Synthetic construct DNA, clone: pF1KB5680, Homo sapiens AKT1 gene for v-akt murine thymoma viral oncogene homolog 1, without stop codon, in Flexi system.
CU674236 - Synthetic construct Homo sapiens gateway clone IMAGE:100018336 5' read AKT1 mRNA.
KF836747 - Homo sapiens AKT1m transcript variant 1 (AKT1) mRNA, 5' UTR and partial cds.
KF836748 - Homo sapiens AKT1m transcript variant 2 (AKT1) mRNA, 5' UTR and partial cds.
KF836749 - Homo sapiens AKT1m transcript variant 3 (AKT1) mRNA, 5' UTR and partial cds.
KF836750 - Homo sapiens AKT1m transcript variant 4 (AKT1) mRNA, 5' UTR and partial cds.
BC001737 - Homo sapiens, clone IMAGE:3354010, mRNA, partial cds.
AK094287 - Homo sapiens cDNA FLJ36968 fis, clone BRACE2006105.
AK131465 - Homo sapiens cDNA FLJ16631 fis, clone TESTI4021482.
AK127193 - Homo sapiens cDNA FLJ45258 fis, clone BRHIP2019884, highly similar to RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1).
JD329707 - Sequence 310731 from Patent EP1572962.
JD402074 - Sequence 383098 from Patent EP1572962.
JD099210 - Sequence 80234 from Patent EP1572962.
JD073445 - Sequence 54469 from Patent EP1572962.
JD482375 - Sequence 463399 from Patent EP1572962.
JD249208 - Sequence 230232 from Patent EP1572962.
JD226294 - Sequence 207318 from Patent EP1572962.
JD449304 - Sequence 430328 from Patent EP1572962.
JD307821 - Sequence 288845 from Patent EP1572962.
AK299310 - Homo sapiens cDNA FLJ53606 complete cds, highly similar to RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1).
JD498438 - Sequence 479462 from Patent EP1572962.
JD076408 - Sequence 57432 from Patent EP1572962.
JD462696 - Sequence 443720 from Patent EP1572962.
X61037 - H.sapiens mRNA for protein kinase B.
BX647722 - Homo sapiens mRNA; cDNA DKFZp686M0424 (from clone DKFZp686M0424).
JD026698 - Sequence 7722 from Patent EP1572962.
JD035230 - Sequence 16254 from Patent EP1572962.
BC063408 - Homo sapiens v-akt murine thymoma viral oncogene homolog 1, mRNA (cDNA clone IMAGE:5212292).
JD480746 - Sequence 461770 from Patent EP1572962.
JD455368 - Sequence 436392 from Patent EP1572962.
JD445287 - Sequence 426311 from Patent EP1572962.
JD400586 - Sequence 381610 from Patent EP1572962.
JD491543 - Sequence 472567 from Patent EP1572962.
JD138546 - Sequence 119570 from Patent EP1572962.
JD386290 - Sequence 367314 from Patent EP1572962.

-  Biochemical and Signaling Pathways
  KEGG - Kyoto Encyclopedia of Genes and Genomes
hsa04010 - MAPK signaling pathway
hsa04012 - ErbB signaling pathway
hsa04062 - Chemokine signaling pathway
hsa04150 - mTOR signaling pathway
hsa04210 - Apoptosis
hsa04370 - VEGF signaling pathway
hsa04510 - Focal adhesion
hsa04530 - Tight junction
hsa04620 - Toll-like receptor signaling pathway
hsa04630 - Jak-STAT signaling pathway
hsa04660 - T cell receptor signaling pathway
hsa04662 - B cell receptor signaling pathway
hsa04664 - Fc epsilon RI signaling pathway
hsa04666 - Fc gamma R-mediated phagocytosis
hsa04722 - Neurotrophin signaling pathway
hsa04910 - Insulin signaling pathway
hsa04914 - Progesterone-mediated oocyte maturation
hsa04920 - Adipocytokine signaling pathway
hsa05142 - Chagas disease
hsa05200 - Pathways in cancer
hsa05210 - Colorectal cancer
hsa05211 - Renal cell carcinoma
hsa05212 - Pancreatic cancer
hsa05213 - Endometrial cancer
hsa05214 - Glioma
hsa05215 - Prostate cancer
hsa05218 - Melanoma
hsa05220 - Chronic myeloid leukemia
hsa05221 - Acute myeloid leukemia
hsa05222 - Small cell lung cancer
hsa05223 - Non-small cell lung cancer

BioCarta from NCI Cancer Genome Anatomy Project
h_aktPathway - AKT Signaling Pathway
h_chemicalPathway - Apoptotic Signaling in Response to DNA Damage
h_hdacPathway - Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK)
h_mTORPathway - mTOR Signaling Pathway
h_nfatPathway - NFAT and Hypertrophy of the heart (Transcription in the broken heart)
h_igf1mtorpathway - Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway
h_il4Pathway - IL 4 signaling pathway
h_telPathway - Telomeres, Telomerase, Cellular Aging, and Immortality
h_gsk3Pathway - Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages
h_trkaPathway - Trka Receptor Signaling Pathway
h_achPathway - Role of nicotinic acetylcholine receptors in the regulation of apoptosis
h_erk5Pathway - Role of Erk5 in Neuronal Survival
h_RacCycDPathway - Influence of Ras and Rho proteins on G1 to S Transition
h_edg1Pathway - Phospholipids as signalling intermediaries
h_no1Pathway - Actions of Nitric Oxide in the Heart
h_p53hypoxiaPathway - Hypoxia and p53 in the Cardiovascular system
h_plcPathway - Phospholipase C Signaling Pathway
h_bcellsurvivalPathway - B Cell Survival Pathway
h_eif4Pathway - Regulation of eIF4e and p70 S6 Kinase
h_hcmvPathway - Human Cytomegalovirus and Map Kinase Pathways
h_igf1rPathway - Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation
h_rasPathway - Ras Signaling Pathway
h_crebPathway - Transcription factor CREB and its extracellular signals
h_gcrPathway - Corticosteroids and cardioprotection
h_longevityPathway - The IGF-1 Receptor and Longevity
h_ptenPathway - PTEN dependent cell cycle arrest and apoptosis
h_tffPathway - Trefoil Factors Initiate Mucosal Healing
h_badPathway - Regulation of BAD phosphorylation
h_gleevecpathway - Inhibition of Cellular Proliferation by Gleevec
h_il2rbPathway - IL-2 Receptor Beta Chain in T cell Activation
h_ptdinsPathway - Phosphoinositides and their downstream targets.

Reactome (by CSHL, EBI, and GO)

Protein P31749 (Reactome details) participates in the following event(s):

R-HSA-8848751 PTK6 binds AKT1
R-HSA-6811504 AKT1 dephosphorylation by PP2A-B56-beta,gamma
R-HSA-202137 AKT1 binds eNOS complex via HSP90
R-HSA-2219536 AKT1 E17K mutant binds PIP2
R-HSA-2399997 AKT1 E17K mutant translocates to the nucleus
R-HSA-2243942 PDPK1 phosphorylates AKT1 E17K mutant
R-HSA-8848758 PTK6 phosphorylates AKT1
R-HSA-198284 PIP3 recruits PDK1 and AKT to the membrane
R-HSA-2317332 PIP3 recruits AKT to the membrane
R-HSA-390329 Dephosphorylation of AKT by PP2A
R-HSA-1497784 The cofactor BH4 is required for electron transfer in the eNOS catalytic cycle
R-HSA-202111 AKT1 phosphorylates eNOS
R-HSA-1497796 BH2 binding can lead to eNOS uncoupling
R-HSA-198298 AKT translocates to the nucleus
R-HSA-199425 PHLPP dephosphorylates S473 in AKT
R-HSA-198270 PDPK1 phosphorylates AKT at T308
R-HSA-450490 Protein Kinase B/Akt phosphorylates BRF1
R-HSA-450499 Protein Kinase B (AKT) phosphorylates KSRP
R-NUL-8939977 Acitvated AKT1 phosphorylates Runx2
R-HSA-377186 Activated Akt1 phosphorylates AKT1S1 (PRAS40)
R-HSA-2243938 AKT1 E17K mutant is phosphorylated by TORC2 complex
R-HSA-2400010 AKT inhibitors block AKT membrane recruitment
R-HSA-2399941 AKT1 E17K mutant phosphorylates BAD
R-HSA-2399966 AKT1 E17K mutant phosphorylates GSK3
R-HSA-2399969 AKT1 E17K mutant phosphorylates p21Cip1 and p27Kip1
R-HSA-2399977 AKT1 E17K mutant phosphorylates AKT1S1 (PRAS40)
R-HSA-2399981 AKT1 E17K mutant phosphorylates MDM2
R-HSA-2399982 AKT1 E17K mutant phosphorylates TSC2, inhibiting it
R-HSA-2399985 AKT1 E17K mutant phosphorylates caspase-9
R-HSA-2400001 AKT1 E17K mutant phosphorylates CHUK (IKKalpha)
R-HSA-2243937 PIP2-bound p-S473-AKT1 mutant binds PIP2-bound PDPK1
R-HSA-2399988 AKT1 E17K mutant phosphorylates NR4A1 (NUR77)
R-HSA-2399992 AKT1 E17K mutant phosphorylates forkhead box transcription factors
R-HSA-2399996 AKT1 E17K mutant phosphorylates CREB1
R-HSA-2399999 AKT1 E17K mutant phosphorylates RSK
R-HSA-1497810 Uncoupled eNOS favours the formation of superoxide
R-HSA-198347 AKT phosphorylates BAD
R-HSA-198371 AKT phosphorylates GSK3
R-HSA-198599 AKT phosphorylates MDM2
R-HSA-198609 AKT phosphorylates TSC2, inhibiting it
R-HSA-198611 AKT phosphorylates IKKalpha
R-HSA-198613 AKT phosphorylates p21Cip1 and p27Kip1
R-HSA-198621 AKT phosphorylates caspase-9
R-HSA-200143 AKT phosphorylates AKT1S1 (PRAS40)
R-HSA-389756 AKT interacts and phosphorylates Cot
R-HSA-1358791 Phosphorylation of USP8 by P-AKT
R-NUL-3139045 AKT phosphorylates Bad
R-HSA-8933446 Active AKT phosphorylates DENND1A and DENND1B in response to insulin signaling
R-HSA-8948757 AKT phosphorylates MKRN1
R-HSA-199298 AKT phosphorylates CREB1
R-HSA-199299 AKT can phosphorylate forkhead box transcription factors
R-HSA-199839 AKT can phosphorylate RSK
R-HSA-199863 AKT can phosphorylate NR4A1 (NUR77)
R-HSA-211164 AKT phosphorylates FOXO1A
R-HSA-6805640 AKT phosphorylates KAT6A
R-HSA-6805785 AKT phosphorylates PHF20
R-HSA-8939963 Activated AKT phosphorylates RUNX2
R-HSA-3769394 AKT phosphorylates CBY1
R-HSA-198640 TORC2 (mTOR) phosphorylates AKT at S473
R-HSA-199443 THEM4 (CTMP) and/or TRIB3 inhibit AKT phosphorylation
R-HSA-432110 Integrin alpha IIb beta3 T779 phosphorylation blocks SHC binding
R-HSA-2317314 AKT binds PDPK1
R-HSA-202127 eNOS synthesizes NO
R-HSA-8849469 PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
R-HSA-6811558 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-203615 eNOS activation
R-HSA-5218920 VEGFR2 mediated vascular permeability
R-HSA-5674400 Constitutive Signaling by AKT1 E17K in Cancer
R-HSA-392451 G beta:gamma signalling through PI3Kgamma
R-HSA-389357 CD28 dependent PI3K/Akt signaling
R-HSA-1257604 PIP3 activates AKT signaling
R-HSA-389513 CTLA4 inhibitory signaling
R-HSA-6785807 Interleukin-4 and 13 signaling
R-HSA-8848021 Signaling by PTK6
R-HSA-199418 Negative regulation of the PI3K/AKT network
R-HSA-1474151 Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
R-HSA-203765 eNOS activation and regulation
R-HSA-4420097 VEGFA-VEGFR2 Pathway
R-HSA-450385 Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
R-HSA-450604 KSRP (KHSRP) binds and destabilizes mRNA
R-HSA-165159 mTOR signalling
R-HSA-2219528 PI3K/AKT Signaling in Cancer
R-HSA-397795 G-protein beta:gamma signalling
R-HSA-389356 CD28 co-stimulation
R-HSA-9006925 Intracellular signaling by second messengers
R-HSA-388841 Costimulation by the CD28 family
R-HSA-449147 Signaling by Interleukins
R-HSA-9006927 Signaling by Non-Receptor Tyrosine Kinases
R-HSA-8978934 Metabolism of cofactors
R-HSA-111447 Activation of BAD and translocation to mitochondria
R-HSA-198323 AKT phosphorylates targets in the cytosol
R-HSA-6804757 Regulation of TP53 Degradation
R-HSA-5628897 TP53 Regulates Metabolic Genes
R-HSA-69202 Cyclin E associated events during G1/S transition
R-HSA-69656 Cyclin A:Cdk2-associated events at S phase entry
R-HSA-1358803 Downregulation of ERBB2:ERBB3 signaling
R-HSA-8876198 RAB GEFs exchange GTP for GDP on RABs
R-HSA-8948751 Regulation of PTEN stability and activity
R-HSA-202131 Metabolism of nitric oxide
R-HSA-194138 Signaling by VEGF
R-HSA-450531 Regulation of mRNA stability by proteins that bind AU-rich elements
R-HSA-198693 AKT phosphorylates targets in the nucleus
R-HSA-211163 AKT-mediated inactivation of FOXO1A
R-HSA-6804758 Regulation of TP53 Activity through Acetylation
R-HSA-6804759 Regulation of TP53 Activity through Association with Co-factors
R-HSA-8941332 RUNX2 regulates genes involved in cell migration
R-HSA-3769402 Deactivation of the beta-catenin transactivating complex
R-HSA-354192 Integrin alphaIIb beta3 signaling
R-HSA-1445148 Translocation of GLUT4 to the plasma membrane
R-HSA-162582 Signal Transduction
R-HSA-5663202 Diseases of signal transduction
R-HSA-388396 GPCR downstream signalling
R-HSA-1280218 Adaptive Immune System
R-HSA-1280215 Cytokine Signaling in Immune system
R-HSA-196854 Metabolism of vitamins and cofactors
R-HSA-114452 Activation of BH3-only proteins
R-HSA-6806003 Regulation of TP53 Expression and Degradation
R-HSA-3700989 Transcriptional Regulation by TP53
R-HSA-69206 G1/S Transition
R-HSA-69242 S Phase
R-HSA-8863795 Downregulation of ERBB2 signaling
R-HSA-9007101 Rab regulation of trafficking
R-HSA-6807070 PTEN Regulation
R-HSA-1430728 Metabolism
R-HSA-9006934 Signaling by Receptor Tyrosine Kinases
R-HSA-8953854 Metabolism of RNA
R-HSA-210745 Regulation of gene expression in beta cells
R-HSA-5633007 Regulation of TP53 Activity
R-HSA-8878166 Transcriptional regulation by RUNX2
R-HSA-201681 TCF dependent signaling in response to WNT
R-HSA-76009 Platelet Aggregation (Plug Formation)
R-HSA-9006921 Integrin signaling
R-HSA-199991 Membrane Trafficking
R-HSA-1643685 Disease
R-HSA-372790 Signaling by GPCR
R-HSA-168256 Immune System
R-HSA-109606 Intrinsic Pathway for Apoptosis
R-HSA-212436 Generic Transcription Pathway
R-HSA-453279 Mitotic G1-G1/S phases
R-HSA-69278 Cell Cycle (Mitotic)
R-HSA-1227986 Signaling by ERBB2
R-HSA-186712 Regulation of beta-cell development
R-HSA-195721 Signaling by WNT
R-HSA-76002 Platelet activation, signaling and aggregation
R-HSA-5653656 Vesicle-mediated transport
R-HSA-109581 Apoptosis
R-HSA-73857 RNA Polymerase II Transcription
R-HSA-1640170 Cell Cycle
R-HSA-1266738 Developmental Biology
R-HSA-109582 Hemostasis
R-HSA-5357801 Programmed Cell Death
R-HSA-74160 Gene expression (Transcription)

-  Other Names for This Gene
  Alternate Gene Symbols: AKT1_HUMAN, B2RAM5, NM_001014432, NP_005154, P31749, PKB, Q9BWB6, RAC
UCSC ID: uc001ypm.3
RefSeq Accession: NM_001014432
Protein: P31749 (aka AKT1_HUMAN or KRAC_HUMAN)
CCDS: CCDS9994.1

-  GeneReviews for This Gene
  GeneReviews article(s) related to gene AKT1:
proteus (Proteus Syndrome)

-  Gene Model Information
 
category: coding nonsense-mediated-decay: no RNA accession: NM_001014432.1
exon count: 15CDS single in 3' UTR: no RNA size: 2878
ORF size: 1443CDS single in intron: no Alignment % ID: 99.93
txCdsPredict score: 3047.00frame shift in genome: no % Coverage: 99.27
has start codon: yes stop codon in genome: no # of Alignments: 1
has end codon: yes retained intron: no # AT/AC introns 0
selenocysteine: no end bleed into intron: 0# strange splices: 0
Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.